Table 1 Clinical characteristics of the patient on admission

IgG (g/L)

20.8

6.36–14.04

IgG1 (g/L)

24.8

4.9–11.4

IgG2 (g/L)

1.87

1.5–6.4

IgG3 (g/L)

0.99

0.2–1.1

IgG4 (g/L)

0.01

0.08–1.4

IgM (g/L)

2.49

0.29–1.21

IgA (g/L)

1.98

0.63–1.79

IgE (U/L)

4.3

< 100

CD 20 (%)

4.91

14–21

CD3 (%)

73.46

64–72.5

CD4 (%)

32.06

29.5–35.5

CD8 (%)

37.58

24–33.5

CD3–CD16 + CD56+ (%)

12.99

11–23

CD4/CD8

0.85

0.9–1.4

ANA

< 1:80

< 1:80

RF (U/ml)

255

0–14

EBVEA–IgG

+

–

EBVCA–IgG

> 750 U/mL

–

EBVCA–IgM

−

–

EBVNA–IgG

> 600 U/mL

–

CMV IgM

−

–

EBV DNA (copies/mL)

−

–

Plasma (day 7)

1.09 × 10⁴

< 5.0 × 10²

Plasma (day 23)

6.96 × 10³

< 5.0 × 10²

Plasma (day 39)

9.55 × 10²

< 5.0 × 10²

Plasma (day 55)

1.22 × 10³

< 5.0 × 10²

B cells (day 7, copies/10⁶ cells)

1.37 × 10⁴

< 5.0 × 10²

T cells (day 7, copies/10⁶ cells)

9.02 × 10⁵

< 5.0 × 10²

NK cells (day 7, copies/10⁶ cells)

1.64 × 10⁴

< 5.0 × 10²

Mitochondrial gene testing

No significant pathogenic gene mutations

–

Whole exome testing

No significant pathogenic gene mutations

–